• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

All Itching Is Not Benign; A Case of Refractory Hypereosinophilic Syndrome Treated with Off Label CD52 Inhibitor-Alemtuzumab
CONCLUSIONOur patient responded well to alemtuzumab, without any notable side effects. Therapy should be reserved due to early and late adverse affects but this agent has proved to be an effective treatment for HES in terms of both complete hematologic response and duration (Strati, P. et. al Clinical Lymphoma, Myeloma & Leukemia 2012). Moreover resistance is not seen, as patients with relapse were able to achieve a second remission. Data about efficacy and safety in the long-term remains lacking, but for treatment resistant and refractory HES, Alemtuzmab may be a suitable choice.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - November 21, 2018 Category: Hematology Authors: Ansari, R., Osuna Salazar, E. N., Sarhill, N., Garcia, L. E., Hanley, J. Tags: 634. Myeloproliferative Syndromes: Clinical Source Type: research

Incidence, clinical characteristics, and outcome of interstitial pneumonia in patients with lymphoma
In conclusion, IP is a life-threatening complication in lymphoma patients. Glucocorticoid therapy with continuous monitoring of chest radiographic changes may be a favourable strategy for treating IP. However, IP may recur, especially in patients re-treated with a similar chemotherapy regimen.
Source: Annals of Hematology - January 1, 2018 Category: Hematology Source Type: research

HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies
Asparaginase is a therapeutic enzyme used to treat leukemia and lymphoma, with immune responses resulting in suboptimal drug exposure and a greater risk of relapse. To elucidate whether there is a genetic component to the mechanism of asparaginase-induced immune responses, we imputed human leukocyte antigen (HLA) alleles in patients of European ancestry enrolled on leukemia trials at St. Jude Children’s Research Hospital (n = 541) and the Children’s Oncology Group (n = 1329). We identified a higher incidence of hypersensitivity and anti-asparaginase antibodies in patients with HLA-DRB1*07:01 alleles (P = 7.5 x ...
Source: Blood - August 21, 2014 Category: Hematology Authors: Fernandez, C. A., Smith, C., Yang, W., Date, M., Bashford, D., Larsen, E., Bowman, W. P., Liu, C., Ramsey, L. B., Chang, T., Turner, V., Loh, M. L., Raetz, E. A., Winick, N. J., Hunger, S. P., Carroll, W. L., Onengut-Gumuscu, S., Chen, W.-M., Concannon, P Tags: Pediatric Hematology, Free Research Articles, Lymphoid Neoplasia, Clinical Trials and Observations Source Type: research

Associations between allergies and risk of hematologic malignancies: Results from the VITamins and lifestyle cohort study
Immune dysregulations associated with allergies may affect cancer cell biology but studies on the relationship between allergies and risk of hematologic malignancies (HM) yielded inconsistent results. Herein, we used the vitamins and Lifestyle (VITAL) cohort to examine this association. From 2000 to 2002, 66,212 participants, aged 50–76, completed a baseline questionnaire on cancer risk factors, medical conditions, allergies, and asthma. Through 2009, incident HMs (n = 681) were identified via linkage to the surveillance, epidemiology, and end results cancer registry. After adjustment for factors possibly associated ...
Source: American Journal of Hematology - November 22, 2013 Category: Hematology Authors: Mazyar Shadman, Emily White, Anneclaire J. Roos, Roland B. Walter Tags: Research Article Source Type: research